Skip to main content

Colorectal Cancer Clinical Trials

Review the colorectal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 422

Yttrium Y-90 Radioembolization before Surgery for Tumor Control and Future Liver Remnant Hypertrophy Patients with Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for the Treatment of Patients with KRAS-Mutant Metastatic Colorectal Cancer
Status: Active
Location: 2 locations
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
Status: Active
Location: 2 locations
Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ProAgio with Fluorouracil, Irinotecan, and Bevacizumab for the Treatment of Advanced or Metastatic Colorectal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Pooled Mutant KRAS-Targeted Long Peptide Vaccine with Balstilimab and Botensilimab for the Treatment of Patients with Stage IV Non-MSI-H/dMMR Colorectal Cancer and Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Trifluridine/Tipiracil in Combination with Talazoparib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Neoadjuvant Chemotherapy Combined with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, SMART TNT Study
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Chemotherapy with Radiation for the Treatment of Rectal Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Status: Active
Location: 2 locations
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adaptive, Individualized Dose Escalation of the FOX Regimen for the Treatment of Metastatic or Locally Advanced/Inoperable Gastrointestinal Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
High Dose Rate Brachytherapy after Neoadjuvant Therapy to Avoid Major Surgery in Patients with Low-Lying Rectal Adenocarcinoma
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado